HENDERSON, NV / ACCESSWIRE / December 11, 2018 / We have found several companies releasing recent news we believe should be on your radar.
Today we are highlighting: Delcath Systems, Inc. (DCTH), KushCo Holdings, Inc. (KSHB), MPX Bioceutical Corporation (MPXEF), Dare Biosciences, Inc. (DARE), and CorMedix, Inc. (NYSE American: CRMD).
One biotech that just released 3rd quarter results you should put on your radar is Delcath Systems, Inc. (DCTH) (Market Cap: $3.023M Share Price: $0.335), an interventional oncology company focused on the treatment of primary and metastatic liver cancers. A few highlights from their announcement include: treating the first patients in their amended Phase 3 clinical trial, raising $7 million, increasing revenue 20% Y/Y, being published in European Radiology, and that's just a few of the highlights from the report.
The company has been making several strides in their clinical trials.
Biotech in general looks ripe for a comeback in the next few weeks, and DCTH could be a major beneficiary.
KushCo Holdings, Inc. (KSHB) (Market Cap: $465.067M Share Price: $5.92) recently reported their 2018 results, revenue was up 177% Year-over-Year to $52.1 million. Gross margins were 24.2% compared with 35.2% in the prior year period, which is primarily related to the year-end inventory adjustments of $2.8 million. Excluding this year end adjustment, gross margins for the year would have been 30%.
____
MPX Bioceutical Corporation (MPXEF) (Market Cap: $280.307M Share Price: $0.6949) just announced record quarterly revenues of $14.7 million for the fiscal second quarter of 2019, versus $4.4 million for the fiscal second quarter of 2018, up 233%.
____
Dare Biosciences, Inc. (DARE), (Market Cap: $9.366M Share Price: $0.82) announced that it has entered into definitive agreements with Hammock Pharmaceuticals, Inc., TriLogic Pharma LLC and MilanaPharm LLC under which Daré acquired the global rights to MP-101 for the treatment of bacterial vaginosis (BV), as well as the rights to utilize the underlying proprietary hydrogel drug delivery technology for any vaginal or urological application in humans.
____
CorMedix, Inc. (NYSE American: CRMD) (Market Cap: $167.947M Share Price: $1.67) recently released their third quarter numbers reporting a loss of $10.2 million in its third quarter. On a per-share basis, the Berkeley Heights, New Jersey-based company said it had a loss of 11 cents. The pharmaceutical and medical device company posted revenue of $372,500 in the period. Its adjusted revenue was $373,000.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communications, LLC